Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Given Novo Nordisk's laser-like focus on developing new therapies to treat type 2 diabetes and obesity, like its blockbuster drugs Ozempic and Wegovy, the likely intent of this deal is to seed its ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

(RTTNews) - Novo Nordisk said that the European Medicines ... with or without type 2 diabetes. The positive opinion is based on results from the STEP HFpEF and STEP HFpEF-DM trials, which showed ...

Novo Nordisk's weight-loss drugs ... Novo's GLP-1 pill that has so far only been approved for diabetes patients. However, only 1.2% of Wegovy prescriptions were paid for by Medicare.

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

A/S fell on Wednesday after Bloomberg reported that Ozempic, Novo Nordisk’s diabetes drug, is ”very likely” to be one of the ...

Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to US$600 million in ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...